{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:58:21Z","timestamp":1768787901964,"version":"3.49.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100009158","name":"Kawasaki Medical School","doi-asserted-by":"publisher","award":["R05B-76"],"award-info":[{"award-number":["R05B-76"]}],"id":[{"id":"10.13039\/501100009158","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009158","name":"Kawasaki Medical School","doi-asserted-by":"publisher","award":["R04B-74"],"award-info":[{"award-number":["R04B-74"]}],"id":[{"id":"10.13039\/501100009158","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009158","name":"Kawasaki Medical School","doi-asserted-by":"publisher","award":["R05B73"],"award-info":[{"award-number":["R05B73"]}],"id":[{"id":"10.13039\/501100009158","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kawasaki Foundation for Medical Science and Medical Welfare"},{"name":"Sanyo Broadcasting Academic, Cultural, and Sports Promotion Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study investigated the impact of Janus kinase inhibitors (JAKi) on NK cell activity and phenotype in patients with RA. While JAKi are effective in achieving low disease activity (LDA), preclinical and pharmacokinetic studies suggest potential effects on NK cells, raising concerns about infection and malignancy risks. However, the extent of these effects in RA patients remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed the cytotoxic activity of peripheral blood NK cells in RA patients with LDA who had been treated with JAKi (n\u2009=\u200985) or TNF inhibitors (TNFi) (n\u2009=\u2009131) for more than three months using a 51Cr-release assay. Propensity score matching was used to adjust for confounders, and multivariable logistic regression identified risk factors for low NK cell activity. NK cell maturation and differentiation were evaluated via flow cytometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>NK cell activity was significantly lower in the JAKi group compared with the TNFi group (median 50% vs 36%, P\u2009=\u20090.002). The proportion of NK and CD56dim cells was reduced, while CD56bright cells were more abundant in the JAKi group. In the JAKi group, glucocorticoid use (odds ratio [OR] 5.36, 95% CI 1.10\u201326.07, P\u2009=\u20090.04) and younger age (&amp;lt;50\u2009years; OR 10.56, 95% CI 2.69\u201341.45, P\u2009&amp;lt;\u20090.01) were independent risk factors for reduced NK cell activity. Notably, herpes zoster incidence was significantly higher in the low NK cell activity group among RA patients younger than 50\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>JAKi treatment significantly impaired NK cell activity and differentiation in RA patients, with age influencing these effects, underscoring important safety concerns.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf308","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T01:29:46Z","timestamp":1749086986000},"page":"5404-5412","source":"Crossref","is-referenced-by-count":2,"title":["NK cell cytotoxicity is markedly reduced in younger patients with RA treated with JAK inhibitors"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4055-3083","authenticated-orcid":false,"given":"Takahiko","family":"Akagi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]},{"name":"Department of Internal Medicine, Fukuyama City Hospital , Fukuyama, Hiroshima,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-077X","authenticated-orcid":false,"given":"Yasumitsu","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-6828","authenticated-orcid":false,"given":"Shunichi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine 1, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3507-0098","authenticated-orcid":false,"given":"Akiko","family":"Nagasu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9798-1287","authenticated-orcid":false,"given":"Shoko","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-0881","authenticated-orcid":false,"given":"Yoshitaka","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1272-2997","authenticated-orcid":false,"given":"Kazuhisa","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School , Kurashiki, Okayama,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2025100315133530700_keaf308-B1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis\u2014common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100315133530700_keaf308-B2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"2025100315133530700_keaf308-B3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025100315133530700_keaf308-B4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100315133530700_keaf308-B5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"2025100315133530700_keaf308-B6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1365-2249.2001.01571.x","article-title":"Association between natural killer cell activity and infection in immunologically normal elderly people","volume":"124","author":"Ogata","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"2025100315133530700_keaf308-B7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025100315133530700_keaf308-B8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025100315133530700_keaf308-B9","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3389\/fimmu.2019.02972","article-title":"JAK inhibition differentially affects NK cell and ILC1 homeostasis","volume":"10","author":"Vian","year":"2019","journal-title":"Front Immunol"},{"key":"2025100315133530700_keaf308-B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025100315133530700_keaf308-B11","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1038\/ncomms12258","article-title":"Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models","volume":"7","author":"Bottos","year":"2016","journal-title":"Nat Commun"},{"key":"2025100315133530700_keaf308-B12","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.40680","article-title":"Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis","volume":"70","author":"Tanaka","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025100315133530700_keaf308-B13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/art.40780","article-title":"Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis","volume":"71","author":"van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025100315133530700_keaf308-B14","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/rheumatology\/keac710","article-title":"Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity","volume":"62","author":"Meudec","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315133530700_keaf308-B15","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.4049\/jimmunol.132.6.2876","article-title":"Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes","volume":"132","author":"Nair","year":"1984","journal-title":"J Immunol"},{"key":"2025100315133530700_keaf308-B16","first-page":"4019","article-title":"Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon","volume":"43","author":"Holbrook","year":"1983","journal-title":"Cancer Res"},{"key":"2025100315133530700_keaf308-B17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/cimm.1997.1138","article-title":"Glucocorticoid regulation of natural cytotoxicity: effects of cortisol on the phenotype and function of a cloned human natural killer cell line","volume":"178","author":"Zhou","year":"1997","journal-title":"Cell Immunol"},{"key":"2025100315133530700_keaf308-B18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbi.2010.07.244","article-title":"Glucocorticoid dysregulation of natural killer cell function through epigenetic modification","volume":"25","author":"Krukowski","year":"2011","journal-title":"Brain Behav Immun"},{"key":"2025100315133530700_keaf308-B19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2025100315133530700_keaf308-B20","doi-asserted-by":"crossref","first-page":"e182390","DOI":"10.1172\/jci.insight.182390","article-title":"NK cell subsets define sustained remission in rheumatoid arthritis","volume":"9","author":"Coyle","year":"2024","journal-title":"JCI Insight"},{"key":"2025100315133530700_keaf308-B21","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"2025100315133530700_keaf308-B22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.humimm.2011.01.009","article-title":"Age-related changes in natural killer cell receptors from childhood through old age","volume":"72","author":"Almeida-Oliveira","year":"2011","journal-title":"Hum Immunol"},{"key":"2025100315133530700_keaf308-B23","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.4049\/jimmunol.1600590","article-title":"Killer cell lectin-like receptor G1 inhibits NK cell function through activation of adenosine 5\u2032-monophosphate-activated protein kinase","volume":"197","author":"M\u00fcller-Durovic","year":"2016","journal-title":"J Immunol"},{"key":"2025100315133530700_keaf308-B24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.humimm.2010.03.014","article-title":"Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset","volume":"71","author":"Hayhoe","year":"2010","journal-title":"Hum Immunol"},{"key":"2025100315133530700_keaf308-B25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1474-9726.2010.00584.x","article-title":"Human NK cells display major phenotypic and functional changes over the life span","volume":"9","author":"Le Garff-Tavernier","year":"2010","journal-title":"Aging Cell"},{"key":"2025100315133530700_keaf308-B26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3389\/fimmu.2013.00499","article-title":"Signatures of human NK cell development and terminal differentiation","volume":"4","author":"Luetke-Eversloh","year":"2013","journal-title":"Front Immunol"},{"key":"2025100315133530700_keaf308-B27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0165-2478(96)02519-9","article-title":"Cytokine sensitivity of human NK cells during immunosenescence. 2. IL2-induced interferon gamma secretion","volume":"50","author":"Krishnaraj","year":"1996","journal-title":"Immunol Lett"},{"key":"2025100315133530700_keaf308-B28","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/cells11061017","article-title":"Aging of the immune system: focus on natural killer cells phenotype and functions","volume":"11","author":"Brauning","year":"2022","journal-title":"Cells"},{"key":"2025100315133530700_keaf308-B29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0048-9697(00)00782-8","article-title":"Lifestyles and mental health status are associated with natural killer cell and lymphokine-activated killer cell activities","volume":"270","author":"Morimoto","year":"2001","journal-title":"Sci Total Environ"},{"key":"2025100315133530700_keaf308-B30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbi.2006.06.002","article-title":"Sleep, fatigue, and NK cell activity in healthy volunteers: significant relationships revealed by within subject analyses","volume":"21","author":"Shakhar","year":"2007","journal-title":"Brain Behav Immun"},{"key":"2025100315133530700_keaf308-B31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0091-7435(92)90068-S","article-title":"Healthy lifestyles are associated with higher natural killer cell activity","volume":"21","author":"Kusaka","year":"1992","journal-title":"Prev Med"},{"key":"2025100315133530700_keaf308-B32","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025100315133530700_keaf308-B33","doi-asserted-by":"crossref","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2025100315133530700_keaf308-B34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2119\/molmed.2014.00252","article-title":"Enrichment of genetic variants for rheumatoid arthritis within T-cell and NK-cell enhancer regions","volume":"21","author":"Freudenberg","year":"2015","journal-title":"Mol Med"},{"key":"2025100315133530700_keaf308-B35","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41598-018-37448-z","article-title":"High percentages and activity of synovial fluid NK cells present in patients with advanced stage active rheumatoid arthritis","volume":"9","author":"Yamin","year":"2019","journal-title":"Sci Rep"},{"key":"2025100315133530700_keaf308-B36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/art.41958","article-title":"Effect of JAK inhibition on the induction of proinflammatory HLA-DR+CD90+ rheumatoid arthritis synovial fibroblasts by interferon-\u03b3","volume":"74","author":"Zhao","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf308\/63437605\/keaf308.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5404\/63437605\/keaf308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5404\/63437605\/keaf308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:13:46Z","timestamp":1759518826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/10\/5404\/8156923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,4]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf308","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,4]]}}}